Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXEL NASDAQ:IBB NASDAQ:REGN NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXELExelixis$49.90+2.5%$44.62$33.76▼$51.63$12.54B0.382.76 million shs2.41 million shsIBBiShares Biotechnology ETF$167.91+2.3%$169.08$119.78▼$179.64$7.80B0.731.71 million shs1.82 million shsREGNRegeneron Pharmaceuticals$649.76+3.1%$739.39$476.49▼$821.11$68.69B0.3787,683 shs1.17 million shsVRTXVertex Pharmaceuticals$430.44-0.9%$444.63$362.50▼$507.92$109.25B0.31.39 million shs1.78 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXELExelixis-2.35%-1.60%+8.42%+9.44%+8.91%IBBiShares Biotechnology ETF+0.18%-4.62%-6.99%-5.97%+34.13%REGNRegeneron Pharmaceuticals+0.10%-12.87%-16.02%-20.43%+5.66%VRTXVertex Pharmaceuticals-0.52%-3.12%-1.56%-7.65%-1.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXELExelixis$49.90+2.5%$44.62$33.76▼$51.63$12.54B0.382.76 million shs2.41 million shsIBBiShares Biotechnology ETF$167.91+2.3%$169.08$119.78▼$179.64$7.80B0.731.71 million shs1.82 million shsREGNRegeneron Pharmaceuticals$649.76+3.1%$739.39$476.49▼$821.11$68.69B0.3787,683 shs1.17 million shsVRTXVertex Pharmaceuticals$430.44-0.9%$444.63$362.50▼$507.92$109.25B0.31.39 million shs1.78 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXELExelixis-2.35%-1.60%+8.42%+9.44%+8.91%IBBiShares Biotechnology ETF+0.18%-4.62%-6.99%-5.97%+34.13%REGNRegeneron Pharmaceuticals+0.10%-12.87%-16.02%-20.43%+5.66%VRTXVertex Pharmaceuticals-0.52%-3.12%-1.56%-7.65%-1.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXELExelixis 2.39Hold$47.35-4.82% DownsideIBBiShares Biotechnology ETF 2.73Moderate Buy$166.04-0.55% DownsideREGNRegeneron Pharmaceuticals 2.70Moderate Buy$792.6523.24% UpsideVRTXVertex Pharmaceuticals 2.88Moderate Buy$555.1729.56% UpsideCurrent Analyst Ratings BreakdownLatest IBB, REGN, VRTX, and EXEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026REGNRegeneron Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,057.00 ➝ $875.005/18/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/18/2026REGNRegeneron Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$900.00 ➝ $730.005/18/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$796.00 ➝ $778.005/18/2026REGNRegeneron Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$950.00 ➝ $850.005/18/2026REGNRegeneron Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$762.00 ➝ $707.005/18/2026REGNRegeneron Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$800.00 ➝ $700.005/18/2026REGNRegeneron Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$875.00 ➝ $855.005/18/2026REGNRegeneron Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$900.00 ➝ $700.005/18/2026REGNRegeneron Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$792.00 ➝ $641.005/7/2026EXELExelixis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $56.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXELExelixis$2.32B5.39$3.02 per share16.46$7.70 per share6.46IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$14.34B4.74$42.88 per share15.00$297.23 per share2.16VRTXVertex Pharmaceuticals$12.00B9.06$17.25 per share24.84$76.29 per share5.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXELExelixis$782.57M$3.0116.5313.481.0535.08%39.89%30.23%8/4/2026 (Estimated)IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$4.50B$41.0415.6715.491.4029.65%13.16%10.17%7/30/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8625.4122.531.8735.51%23.86%17.13%8/3/2026 (Estimated)Latest IBB, REGN, VRTX, and EXEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026EXELExelixis$0.75$0.87+$0.12$0.8138$607.51 million$610.81 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEXELExelixisN/AN/AN/AN/AN/AIBBiShares Biotechnology ETF$0.390.23%N/AN/AN/AREGNRegeneron Pharmaceuticals$3.760.58%N/A9.16%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest IBB, REGN, VRTX, and EXEL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.59%5/20/20265/20/20266/4/20263/16/2026IBBiShares Biotechnology ETFQuarterly$0.12180.29%3/17/20263/17/20263/20/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXELExelixisN/A3.263.19IBBiShares Biotechnology ETFN/AN/AN/AREGNRegeneron Pharmaceuticals0.063.572.96VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXELExelixis85.27%IBBiShares Biotechnology ETF62.45%REGNRegeneron Pharmaceuticals83.31%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipEXELExelixis2.60%IBBiShares Biotechnology ETFN/AREGNRegeneron Pharmaceuticals6.97%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXELExelixis1,077251.35 million244.82 millionOptionableIBBiShares Biotechnology ETFN/A46.45 millionN/AOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableIBB, REGN, VRTX, and EXEL HeadlinesRecent News About These Companies31,281 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.May 20 at 3:54 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Stake Raised by Atle Fund Management ABMay 20 at 3:10 AM | marketbeat.comVertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 5:01 PM | seekingalpha.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItMay 19 at 3:16 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItMay 19 at 10:01 AM | zacks.comVertex Pharmaceuticals Incorporated $VRTX Holdings Decreased by Tredje AP fondenMay 19 at 6:52 AM | marketbeat.comResona Asset Management Co. Ltd. Has $40.63 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:43 AM | marketbeat.comProfund Advisors LLC Purchases 2,423 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comProShare Advisors LLC Grows Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comAMF Tjanstepension AB Buys 83,487 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 3:11 AM | marketbeat.comVertex Steps Into Autoimmune Care: Mid-Stage Myasthenia Gravis Trial Shows Growing Pipeline AmbitionMay 18 at 12:50 PM | tipranks.comNorth Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 5:49 AM | marketbeat.comCanada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 3:57 AM | marketbeat.comFY2026 Earnings Estimate for VRTX Issued By Erste Group BankMay 18 at 1:23 AM | marketbeat.comLeuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTXMay 17 at 6:49 AM | marketbeat.comSTF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTXMay 17 at 6:25 AM | marketbeat.comInsider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Sells $3,144,600.00 in StockMay 17 at 4:37 AM | americanbankingnews.comVertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management ASMay 16, 2026 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by AnalystsMay 16, 2026 | marketbeat.comAllworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTXMay 16, 2026 | marketbeat.comVertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitorsMay 15, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Norwegian Cruise Line Cuts Outlook as Headwinds BuildBy Jennifer Ryan Woods | May 5, 2026Comparing 3 Cruise Stocks: Which Has the Most Upside in 2026?By Jennifer Ryan Woods | April 21, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026IBB, REGN, VRTX, and EXEL Company DescriptionsExelixis NASDAQ:EXEL$49.90 +1.23 (+2.53%) Closing price 04:00 PM EasternExtended Trading$49.31 -0.59 (-1.19%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.iShares Biotechnology ETF NASDAQ:IBB$167.91 +3.72 (+2.27%) As of 04:00 PM EasterniShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Regeneron Pharmaceuticals NASDAQ:REGN$649.76 +19.46 (+3.09%) Closing price 04:00 PM EasternExtended Trading$643.47 -6.29 (-0.97%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Vertex Pharmaceuticals NASDAQ:VRTX$430.44 -3.87 (-0.89%) Closing price 04:00 PM EasternExtended Trading$429.20 -1.24 (-0.29%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
